Close this search box.

Phil Pang exiting Vir as CMO

ARTICLE | Management Tracks

Plus: Arshad Khanani named chief medical adviser at Opthea and Smart Immune names a chair

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

February 21, 2024 1:03 AM UTC

EVP and CMO Phil Pang will leave Vir Biotechnology Inc. (NASDAQ:VIR) at the end of March, to spend more time with his family. Pang joined Vir in 2016 as SVP, and played a major part in the development of sotrovimab during the peak of the COVID-19 pandemic. Vir has begun the search for a successor. 

Arshad Khanani became chief medical adviser at Opthea Ltd. (ASX:OPT; NASDAQ:OPT), which is developing therapies for retinal diseases with backing from The Carlyle Group (NASDAQ:CG) and Abingworth. Khanani is managing partner, director of clinical research at Sierra Eye Associates. …